Company intelligence / Profile preview
Glia
Geneva, Geneva, Switzerlandgliapharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GliaPharm has developed a proprietary drug discovery platform focused on glial cell pathways. Its lead candidate, GP‑119, has demonstrated safety and efficacy in preclinical models by enhancing brain energy metabolism and restoring memory function. The company has completed early CMC and safety studies and aims to progress to IND-enabling regulatory preclinical studies with support from the Alzheimer’s Drug Discovery Foundation. No clinical trial results are available yet.
- Therapeutic areas
- Rare DiseasesPsychiatryNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
UMC Utrecht (academic collaboration)Evotec (‘INDiGO Select’ program for early CMC/ADME-DMPK/Safety-Tox work)
Beyond the preview
Go deeper on Glia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glia.